How to buy Cellectar Biosciences stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cellectar Biosciences stock

Own Cellectar Biosciences stock in just a few minutes.

Cellectar Biosciences, Inc is a biotechnology business based in the US. Cellectar Biosciences shares (CLRB) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectar Biosciences employs 11 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Cellectar Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CLRB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cellectar Biosciences share price

Use our graph to track the performance of CLRB stocks over time.

Cellectar Biosciences shares at a glance

Information last updated 2021-04-15.
52-week range$1.01 - $2.98
50-day moving average $1.74
200-day moving average $1.72
Wall St. target price$5.98
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.13

Buy Cellectar Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cellectar Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cellectar Biosciences financials

Gross profit TTM $0
Return on assets TTM -26.95%
Return on equity TTM -47.28%
Profit margin 0%
Book value $0.77
Market capitalisation $70.7 million

TTM: trailing 12 months

Shorting Cellectar Biosciences shares

There are currently 2.1 million Cellectar Biosciences shares held short by investors – that's known as Cellectar Biosciences's "short interest". This figure is 1.2% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting Cellectar Biosciences shares can be evaluated.

Cellectar Biosciences's "short interest ratio" (SIR)

Cellectar Biosciences's "short interest ratio" (SIR) is the quantity of Cellectar Biosciences shares currently shorted divided by the average quantity of Cellectar Biosciences shares traded daily (recently around 1.3 million). Cellectar Biosciences's SIR currently stands at 1.61. In other words for every 100,000 Cellectar Biosciences shares traded daily on the market, roughly 1610 shares are currently held short.

However Cellectar Biosciences's short interest can also be evaluated against the total number of Cellectar Biosciences shares, or, against the total number of tradable Cellectar Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cellectar Biosciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Cellectar Biosciences shares in existence, roughly 40 shares are currently held short) or 0.0423% of the tradable shares (for every 100,000 tradable Cellectar Biosciences shares, roughly 42 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cellectar Biosciences.

Find out more about how you can short Cellectar Biosciences stock.

Cellectar Biosciences share dividends

We're not expecting Cellectar Biosciences to pay a dividend over the next 12 months.

Have Cellectar Biosciences's shares ever split?

Cellectar Biosciences's shares were split on a 1:10 basis on 16 July 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellectar Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cellectar Biosciences shares which in turn could have impacted Cellectar Biosciences's share price.

Cellectar Biosciences share price volatility

Over the last 12 months, Cellectar Biosciences's shares have ranged in value from as little as $1.01 up to $2.98. A popular way to gauge a stock's volatility is its "beta".

CLRB.US volatility(beta: 1.73)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectar Biosciences's is 1.7303. This would suggest that Cellectar Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cellectar Biosciences overview

Cellectar Biosciences, Inc. , a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site